DrugPatentWatch Database Preview
« Back to Dashboard
The generic ingredient in TRULANCE is plecanatide. One supplier is listed for this compound. Additional details are available on the plecanatide profile page.
Generic Entry Opportunity Date for 208745
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 208745
|Mechanism of Action||Guanylate Cyclase Activators |
Suppliers and Packaging for NDA: 208745
Profile for product number 001
|Approval Date:||Jan 19, 2017||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Jan 19, 2022|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Regulatory Exclusivity Expiration:||Jan 24, 2021|
|Regulatory Exclusivity Use:||TREATMENT IN ADULT PATIENTS FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)|
|Patent:||➤ Try a Free Trial||Patent Expiration:||Jun 5, 2034||Product Flag?||Substance Flag?||Y||Delist Request?|
Complete Access Available with Subscription